Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax (Nasdaq:SNDX) announced that four Revuforj (revumenib) abstracts were accepted for presentation at ASCO 2026, including an oral post-transplant maintenance study in 21 adults and children with acute leukemia.
Additional posters cover revumenib pharmacokinetics and designs of two phase 3 trials in newly diagnosed NPM1m or KMT2Ar AML.
Syndax Pharmaceuticals (Nasdaq:SNDX) announced participation in several upcoming investor conferences featuring fireside chats with CEO Michael A. Metzger and the management team.
Events include TD Cowen’s Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference, with live and replay webcasts via Syndax’s investor website.
Syndax (Nasdaq:SNDX) announced that 12 abstracts featuring Revuforj® (revumenib) were accepted for EHA 2026, covering real‑world, frontline, relapsed/refractory, and post‑transplant acute leukemia settings.
Data span KMT2Ar, NPM1m, and NUP98r leukemias and include trials in progress, reinforcing Syndax’s focus on menin inhibition in AML.
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on May 1, 2026, to eight new employees to purchase up to 162,100 shares under its 2023 Inducement Plan. The stock options vest over four years: 25% at one year, then 1/48th monthly over the following 36 months, subject to continued service.
Syndax (Nasdaq: SNDX) reported $64.9M total revenue in 1Q26, including $48.9M Revuforj net revenue and $15.9M Niktimvo collaboration revenue. Cash, cash equivalents and short-term investments were $352.1M. Syndax posted a net loss attributable to common stockholders of $42.7M ($0.48/share). R&D was $58.8M and SG&A was $37.6M. The company expects combined R&D plus SG&A of ~$400M for 2026 (excluding ~$50M non-cash stock comp) and highlighted upcoming data readouts in 2Q26 and topline axatilimab Phase 2 data in 4Q26.
Syndax Pharmaceuticals (Nasdaq: SNDX) will report first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET.
Access the live audio webcast and slides via the Investors Events & Presentations page or use Conference ID Syndax1Q26 with domestic dial-in 800-590-8290 or international dial-in 240-690-8800. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement stock option awards on April 1, 2026, granting up to 228,500 shares to eight new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at one year, then monthly vesting over 36 months, subject to continued service.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards granted on March 1, 2026. The company granted options to purchase up to 81,600 shares of common stock to three new employees under its 2023 Inducement Plan.
The options vest over four years: 25% after one year, then 1/48th monthly for 36 months, subject to continued service.
Syndax (NASDAQ: SNDX) reported Q4 2025 revenue $68.7M and FY2025 revenue $172.4M, driven by Revuforj net sales of $44.2M in Q4 ($124.8M FY2025) and Niktimvo net sales of $56.0M in Q4 ($151.6M FY2025).
The company had $394.1M in cash and equivalents at year-end, completed Phase 2 IPF enrollment for axatilimab, and expects 2026 R&D plus SG&A of ~$400M while targeting profitability from product and collaboration revenue.
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.